Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches

Antonella Antonelli, Willy A. Noort, Jenny Jaques, Bauke de Boer, Regina de Jong-Korlaar, Annet Z. Brouwers-Vos, Linda Lubbers-Aalders, Jeroen F. van Velzen, Andries C. Bloem, Huipin Yuan, Joost D. de Bruijn, Gert J. Ossenkoppele, Anton C. M. Martens, Edo Vellenga, Richard W. J. Groen, Jan Jacob Schuringa

Blood (2016) 128 (25): 2949–2959.

https://doi.org/10.1182/blood-2016-05-719021

Published: 2016

Includes: Supplemental data

Journal Articles

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood (2016) 128 (19): 2297–2306.

https://doi.org/10.1182/blood-2016-07-729236

Published: 2016

Includes: Supplemental data

Journal Articles

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy E. Axel, Khaja Syed, Richard W. J. Groen, Mark van Duin, Pieter Sonneveld, Monique C. Minnema, Sonja Zweegman, Christopher Chiu, Andries C. Bloem, Tuna Mutis, Henk M. Lokhorst, A. Kate Sasser, Niels W. C. J. van de Donk

Blood (2016) 128 (7): 959–970.

https://doi.org/10.1182/blood-2016-03-703439

Published: 2016

Includes: Supplemental data

Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD

Blood (2013) 122 (21): 287.

https://doi.org/10.1182/blood.V122.21.287.287

Published: 2013

Journal Articles

Novel Bone Marrow Failure Syndrome Due to a Deletion of the EVI1/Mecom Gene.

Lars T. van der Veken, PhD, Marc Bierings, Merel Maiburg, MD, Floris Groenendaal, MD, PhD, Andries C Bloem, PhD, Nine V. Knoers, MD, PhD, Arjan Buijs, PhD

Blood (2012) 120 (21): 2368.

https://doi.org/10.1182/blood.V120.21.2368.2368

Published: 2012

Journal Articles

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Frans M Hofhuis, Berris Van Kessel, Jeroen F Van Velzen, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Andries C Bloem, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 940.

https://doi.org/10.1182/blood.V120.21.940.940

Published: 2012

Journal Articles

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

Blood (2012) 120 (3): e9–e16.

https://doi.org/10.1182/blood-2012-03-414920

Published: 2012

Includes: Supplemental data

Journal Articles

Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.

Robbert M Spaapen, Kelly van den Oudenalder, Maureen van Elk, Tineke Aarts, Teun Guichelaar, Richard WJ Groen, Andries C Bloem, Gert Storm, Anton C Martens, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD

Blood (2009) 114 (22): 1333.

https://doi.org/10.1182/blood.V114.22.1333.1333

Published: 2009

Journal Articles

A Single Nucleotide Polymorphism in CD19 Defines a Novel Target for Immunotherapy of B Cell Malignancies with CD4 + Cytotoxic T Cells.

Robbert M. Spaapen, MSc, Henk M. Lokhorst, MD PhD, Kelly van den Oudenalder, Brith Otterud, PhD, Harry Dolstra, PhD, Mark Leppert, PhD, Monique C. Minnema, MD PhD, Andries C. Bloem, PhD, Tuna Mutis, MD PhD

Blood (2007) 110 (11): 1798.

https://doi.org/10.1182/blood.V110.11.1798.1798

Published: 2007

Journal Articles

A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.

Henk M. Lokhorst, MD, PhD, Niels van de Donk, MD, PhD, Ellen van de Spek, MD, Okke de Weerdt, MD, Rene van de Griend, MD, PhD, Shulamiet Wittebol, MD, Leo F. Verdonck, MD, PhD, Andries C. Bloem, MD, PhD

Blood (2004) 104 (11): 3458.

https://doi.org/10.1182/blood.V104.11.3458.3458

Published: 2004

Journal Articles

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

Niels W. C. J. van de Donk, Marloes M. J. Kamphuis, Berris van Kessel, Henk M. Lokhorst, Andries C. Bloem

Blood (2003) 102 (9): 3354–3362.

https://doi.org/10.1182/blood-2003-03-0970

Published: 2003

Journal Articles

Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma

Laurens Laterveer, Leo F. Verdonck, Ton Peeters, Erik Borst, Andries C. Bloem, Henk M. Lokhorst

Blood (2003) 101 (3): 1201.

https://doi.org/10.1182/blood-2002-09-2977

Published: 2003

NARROW

Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Novel Bone Marrow Failure Syndrome Due to a Deletion of the EVI1/Mecom Gene.

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.

A Single Nucleotide Polymorphism in CD19 Defines a Novel Target for Immunotherapy of B Cell Malignancies with CD4 + Cytotoxic T Cells.

A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only